
Experimental cancer vaccine from Merck and Moderna shows promising results in late-stage melanoma trial
Merck and Moderna announced positive initial results from their first late-stage trial of an experimental personalized cancer vaccine combined with Merck's immunotherapy Keytruda. The phase three trial involving over 1,100 melanoma patients showed th...


